Contents

Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization (MYRROR)

June 1, 2015

Clinical trial

Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.

Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi.

Ophthalmology. 2015 Jun;122(6):1220-7.
Full text | Metrics.

Main finding: Intravitreal aflibercept 2 mg was effective for treatment of myopic CNV, with a limited number of injections given within the first 8 weeks.

 

  • Purpose: To evaluate intravitreal aflibercept in patients with myopic choroidal neovascularization
  • Study type: Randomized Controlled Trial
  • Condition: Myopic Choroidal Neovascularization

Participants: ≥18 years, high myopia (≤−6.0 diopters or axial length of ≥26.5 mm), active subfoveal/juxtafoveal myopic CNV, BCVA 20/40-20/200

 

  • n=122

 

Intervention:

 

Group 1: Intravitreal Aflibercept 2mg at baseline, then q4weekly PRN if meet retreatment criteriae
Group 2: Sham q4weekly until week 20, then intravitreal Ablibercept at week 24 and q4weekly PRN if meet retreatment criteriae thereafter

 

Outcomes Time period AFLI Sham/AFLI
VA change (letters) 24 weeks +12.1 -2
48 weeks +13.5 +3.9
Number of injections (over 48 weeks) 2 3

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed